S&P ASX All Technology

US Dollar vs AUD

Level up your trading with our powerful tools and real-time insights all in one place.

Get Started

TRDA Entrada Therapeutics Inc

17.14

-0.09 (-0.52%)

After Hours

Last Updated: 08:30:00

Delayed by 15 minutes

Form 144 - Report of proposed sale of securities

="/Images/box-checked.jpg" alt="Checkbox checked">

144: Remarks and Signature

Remarks

Date of Notice

08/16/2024

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

05/08/2024

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

/s/ Nathan Dowden

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

Entrada Therapeutics (NASDAQ:TRDA)
Historical Stock Chart
From Oct 2024 to Nov 2024

Click Here for more Entrada Therapeutics Charts.

Entrada Therapeutics (NASDAQ:TRDA)
Historical Stock Chart
From Nov 2023 to Nov 2024

Click Here for more Entrada Therapeutics Charts.

Entrada Therapeutics Inc News

Form 4 - Statement of changes in beneficial ownership of securities
Saturday 19 October 2024 (2 weeks ago) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Thursday 17 October 2024 (2 weeks ago) • Edgar (US Regulatory)

Entrada Therapeutics Presents New Data Supporting its Expanding Duchenne Franchise at the 29th Annual Congress of the World Muscle Society
Wednesday 9 October 2024 (3 weeks ago) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Tuesday 1 October 2024 (1 month ago) • Edgar (US Regulatory)

Entrada Therapeutics Promotes Natarajan Sethuraman, PhD, to President of Research and Development
Tuesday 24 September 2024 (1 month ago) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Wednesday 11 September 2024 (2 months ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Wednesday 11 September 2024 (2 months ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Wednesday 11 September 2024 (2 months ago) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Tuesday 10 September 2024 (2 months ago) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Saturday 7 September 2024 (2 months ago) • Edgar (US Regulatory)

Entrada Therapeutics Announces Recipients of Second Annual Diversity, Representation, Equity and Advocacy MatterS (DREAMS) Grant Program
Friday 6 September 2024 (2 months ago) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Friday 6 September 2024 (2 months ago) • Edgar (US Regulatory)

More Entrada Therapeutics Inc News Articles

Woodside Petroleum

Australia And New Zealan...

National Australia Bank

S&P ASX 300 Metals and M...

JP Morgan Chase

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions